Avid Bioservices Inc (CDMO)

[sunstar]

Cotara has Orphan Drug Status, Fast Track Designation and has shown very significant increases in GBM survival times: More than 82 weeks compared to the standard of care's 24 weeks. Peregrine will be presenting new interim data at the 2010 Congress of Neurological Surgeons Annual Meeting in San Francisco, California, October 16-21, 2010. Here are two previous Cotara presentation slides. The first shows the dramatic increase in survival in patients with multiple recurrences of GBM coming from Cotara teatment in a dosing study compared to the current standard of care drug:



Here is the market snapshot from 2006 of the current standard of care:



Here are the two Peregrine Cotara trials:

http://www.clinicaltrials.gov/ct2/show/NCT00509301?term=cotara&rank=2

http://www.clinicaltrials.gov/ct2/show/NCT00677716?term=cotara&rank=1

sunstar